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Abstract
Background: Health care policies, including drug-funding policies, influence physician practice.
Funding policies are especially important in the area of cancer care since cancer is a leading cause
of death that is responsible for a significant level of health care expenditures. Recognizing the rising
cost of cancer therapies, Cancer Care Ontario (CCO) established a funding process to provide
access to new, effective agents through a "New Drug Funding Program" (NDFP). The purpose of
this study is to describe oncologists' perceptions of the impact of NDFP priority setting decisions
on their practice.
Methods: This is a qualitative study involving semi-structured, in-depth interviews with 46 medical
oncologists in Ontario. Oncologists were asked to describe the impact of CCO's NDFP drug
funding decisions on their practice. Analysis of interview transcripts commenced with data
collection.
Results: Our key finding is that many of the medical oncologists who participated in this study did
not accept limits when policy decisions limit access to cancer drugs they feel would benefit their
patients. Moreover, overcoming those limits had a significant impact on oncologists' practice in
terms of how they spend their time and energy and their relationship with patients.
Conclusion: When priority setting decisions limit access to cancer medications, many oncologists'
efforts to overcome those limits have a significant impact on their practice. Policy makers need to
seriously consider the implications of their decisions on physicians, who may go to considerable
effort to circumvent their policies in the name of patient advocacy.
Background
Physician practice is a key determinant of health care out-
comes, expenditures and quality of care[1,2]. Health care
policies, including drug-funding policies, have a major
influence on physician practice [1]. However, to our
knowledge, there are no studies of the effect of drug fund-
ing policies on oncologist practice. Funding policies are
especially important in the area of cancer care for several
reasons. Cancer is one of the leading causes of death in
Canada. It is estimated that there will be 153,100 new
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cases of cancer and 70,400 cancer deaths in Canada in
2006[3]. Beyond its human toll, cancer accounts for 8.3%
of health care expenditures in Canada[4]. A 1997 study
estimated that through direct and indirect expenditures,
cancer cost the Canadian economy 13 billion Canadian
dollars in 1993[4]. The practice of oncologists therefore
has a significant effect on the health of Canadians and
health care expenditures.
In recognition of the rising costs of new cancer drugs,
CCO's NDFP was established in 1995 to cover the cost of
certain new and expensive IV cancer drugs. The NDFP
worked in concert with the CCO Practice Guideline Initi-
ative (CCOPGI), which involves a formal and rigorous
process of evidence review, knowledge synthesis and con-
sensus development by medical oncology content and
methodology experts in Ontario[5]. Until 2004 (and at
the time of this study), a "Policy Advisory Committee"
(consisting of administrators, oncologists, oncology
researchers, a pharmacist, an ethicist, patients, and mem-
bers of the public) made funding recommendations to the
NDFP based on a rigorous review of practice guidelines
from the CCOPGI and their assessment of the quality of
evidence, benefits observed and costs of the new medica-
tions[6].
The specific goal of the NDFP was to ensure equitable
access for patients to newly available systemic cancer treat-
ments that have been proven to be effective for their con-
dition as stated in CCO Practice Guidelines. The program
reimburses hospitals and cancer centres for drugs admin-
istered to patients who meet specific eligibility criteria.
This program has grown from a $7 million Canadian dol-
lars program funding 6 drugs for 2354 patients in 1997/
98 to a $64 million Canadian dollars program funding 16
drugs for over 14,000 patients in 2003/04. Although the
process and rationales used for these decisions have been
studied in detail [6-8], the impact of these policies on
medical oncologists' practice has not been studied. The
purpose of this study is to describe medical oncologists'
perceptions of how priority setting decisions for new can-
cer drugs affected their practice.
Methods
Design
This was a qualitative study involving in-depth interviews
with medical oncologists in Ontario in 2002/2003.
Participants/setting
Medical oncologists from across Ontario in a variety of
practice settings. There were approximately 140 medical
oncologists in Ontario at the time of the study. Medical
oncologists were identified from publicly available
sources (College of Physicians and Surgeons of Ontario
website and the Canadian Medical Directory). Purposive
sampling targeted oncologists who had been practicing
for at least 5 years were so that they were able to comment
on their practice before and after the advent of the NDFP.
Participants were identified from a variety of practice set-
tings: i.e. comprehensive cancer centres, general hospitals
and from both small and large centres.
Data collection
In-depth, semi-structured, open-ended interviews were
conducted with 46 oncologists (for demographic infor-
mation see Table 1), in person or by phone, and were
audiotaped and transcribed. Participants were asked to
describe how CCO's NDFP decisions have affected their
practice. The interviewers pursued and clarified informa-
tion about emerging themes. Interviews continued until
Table 1: Demographic Information
Sex
Female 10
Male 36
Years Practicing 
Oncology
> 30 4
>20 11
>10 24
5–9 7
Country Where 
Graduated From Medical 
School
Canada 39
Europe 4
Asia 3
Practice Details
Group Practice 39
Solo Practice 7
Comprehensive Cancer Centre 25
Other 21
University Hospital 24
Community Hospital 22
Involvement in CCO 
Practice Guideline 
Initiative
Participant 18
Non-Participant 25
Unknown 3
Region (By Ontario local 
health integration 
network)
Toronto Central 14
Central East 7
Mississauga Halton 6
Champlain (Ottawa Region) 4
South West (London Region) 3
Hamilton Niagara 3
South East (Kingston Region) 2
Central West 2
Central 2
Waterloo Wellington 1
North Simcoe Muskoka 1
North East 1BMC Health Services Research 2007, 7:193 http://www.biomedcentral.com/1472-6963/7/193
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themes were "saturated" (ie no further new concepts were
emerging from interviews.). An initial interview guide was
developed (appendix 1) and, as is typical in qualitative
research, was revised during the study to explore emerging
themes.
Data analysis
Data analysis proceeded concurrently with data collec-
tion. Interview transcripts were read and participants'
views regarding the impact of drug funding decisions on
their practice were identified and coded. Coded units were
labelled as specific concepts relating to impact on practice.
Codes were continuously compared within and between
transcripts to ensure consistency and comprehensiveness.
Similar concepts were grouped together under overarch-
ing themes and the data were recoded by theme. The
themes were then organized according to perceived
importance, which was based on both prevalence and the
participants' emphasis. Finally, descriptions of the themes
were developed using the participants' own words.
The trustworthiness of our findings was enhanced in three
ways. First, three investigators coded the raw data to
ensure the authenticity of the coding scheme; the final
coding scheme was developed by consensus and used for
the analysis. Second, another investigator familiar with
the data participated in developing the interpretation.
Third, a draft of this paper was endorsed by participants in
a "member check."
Ethics
This study was approved by the Research Ethics Board at
Sunnybrook and Women's College Health Sciences Cen-
tre. All participants provided informed consent for the
interview.
Results
Our key finding is that many of the medical oncologists
who participated in this study did not accept limits when
policy decisions limit access to cancer drugs they feel
would benefit their patients. Moreover, overcoming those
limits had a significant impact on oncologists' practice in
terms of how they spend their time and energy and their
relationship with patients. In the end, however, the per-
ception of most oncologists is that they get what they
think will maintain the quality of patient care.
Five key themes emerged from the analysis including: 1.
Access to medications, 2. Overcoming limits to access, 3.
Impact on the physician-patient relationship, 4. Disen-
gagement of clinicians from priority setting process and 5.
Quality of care. Verbatim quotes from participants are
included for illustration.
Access to medications
Participants acknowledged that the NDFP had a rigorous
process and had improved the evaluation of cancer drugs
and access to drugs approved by the process:
[The NDFP] has been a great help in terms of treatment of
cancer patients... It incorporates some of the practice guide-
lines into place so that people are not using drugs at random
that may be very expensive. It has also provided me the
opportunity to ... provide these patients with some of the
expensive drugs which otherwise our pharmacy would not
be able to...So I think it has actually, in general, improved
... the quality of care ... that we are able to provide to our
patients.
However they also expressed significant concern about
limits on access to drugs. Some oncologists were con-
cerned that the limitations imposed within the funding
guidelines did not allow them the flexibility required to
make treatment decisions for individual patients. Others
felt that there was often a significant time-lag between
demonstration of a drug's efficacy and a funding decision
by the NDFP, although participants felt that this was
improving over time:
And so – and in many ways it's restricted our ability to use
these drugs more than existed before the program existed,
... I find it very slow ... certain categories of patients that
can be well defined. But there are also patients who don't
fit into the normal situations ... The way the CCO program
is, it has very precise indications for drugs. And patients
who fall outside those precise indications, tough.
Overcoming limits to access
When the NDFP limited access to what they felt would be
effective medications for their patients, participants gener-
ally found a way to get the medications they wanted for
their patients. However, overcoming the limits and get-
ting these medications required significant stress and
time. The following quotation illustrates this "hassle fac-
tor":
...We call up the drug company. We spoke to _____ Hospi-
tal. We spoke to CCO. I spoke to _______ of the ______
Disease Site Group. We then called the company; we called
two MPP's, and we called the third-party insurer from one
of the patients who had drug coverage.
If the NDFP would not fund the drug they wanted for their
patients, many physicians would spend considerable time
and effort finding an alternate funding source for the
drug. The alternate funding sources were quite varied and
included enrolling a patient on a clinical trial if they were
eligible, getting the local hospital to pay for the drug,
appealing to another government funding program forBMC Health Services Research 2007, 7:193 http://www.biomedcentral.com/1472-6963/7/193
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non-IV drugs, looking for support from local charities,
using leftover drug supplies from patients who had pro-
cured funding for a drug and "gaming" the system or lying
on forms so that patients would fit funding criteria for a
drug.
One of the participants explained:
...you have to put the code in why this patient should get
funding from the government for this drug, and they don't
always fit the criteria so you wind up lying...because you
want to help your patients.
These activities were time-consuming and contributed to
the physicians' stress. To reduce the time spent on these
matters, some participants would delegate tasks associ-
ated with seeking alternate funding sources to administra-
tive assistants, nurses, pharmacists or social workers.
Impact on physician-patient relationship
Priority setting decisions had a significant impact on dis-
cussions oncologists had with their patients, including the
time spent on discussions with patients, moral distress
regarding those discussions with patients, as well as forc-
ing uncomfortable discussions with patients. When a drug
was funded by the NDFP, participants felt that less discus-
sion was necessary but there was still significant time
needed to discuss drugs where access was limited.
Many participants reported that funding issues led to
uncomfortable discussions with patients, including angry
responses from patients who were told that certain treat-
ment options were not available due to funding con-
straints. Concern was expressed regarding how these
discussions would impact patient trust. One participant
explained:
Once in a while a patient might feel uncomfortable and
they don't come back to see me any more and then remain
in the centre and most of our colleagues in the centre are
quite understanding.
Situations where a particular drug was not funded created
moral distress for many participants. Some felt it was
important to avoid mentioning funding issues in order to
protect patients from added anxiety while others felt that
fully informing patients meant that they must explain that
certain treatments were not funded.
Disengagement from the funding processes
Participants reported that they did not feel engaged in the
NDFP decision-making process because of the perceived
inflexibility of some funding guidelines, the time and
stress associated seeking alternate funding sources and
lack of a formal appeals mechanism.
Quality of care
Most participants did not perceive the NDFP as affecting
overall quality of care. Either drugs were funded by the
NDFP or physicians overcame limits to drugs not funded
by the NDFP. One oncologist's response summarizes this
sentiment:
We would have provided the drugs regardless of the fund-
ing. So it doesn't make any difference to the pattern of prac-
tice we have. It helps balance the hospital budget.
However, this perception was not universal. Some partic-
ipants acknowledged not being able to access medications
with "level 1" evidence. One participant pointed out:
the funding process as dictated by guidelines restricts drugs
to a certain group of people. Some oncologists may choose to
find access through different means, some not ... it takes a
huge amount of time to try and find access through differ-
ent means thus taking time away from our patients.
Discussion
While previous studies have described funding policy
development for new and expensive cancer drugs, this is
the first study to describe oncologists' perceptions of the
impact of those policies on oncologists' practice. We
found that many oncologists do not accept limits to drugs
they believe to be necessary for their patients, even when
the decisions are made by a priority setting committee
specifically appointed to make funding policy decisions.
Time and energy spent overcoming those limits have a
substantial impact on their practice. In the end, however,
most oncologists perceive that the quality of care they pro-
vide for their patients is maintained – because they do
what they can to get the drugs that are not funded.
Three previous studies have described priority setting for
cancer drugs, focusing on the decision making process
and reasoning used by priority setting bodies [6-8]. While
these studies provide important information on how pri-
ority setting decisions are made, our study adds important
information about how the priority setting policies that
are developed affect physician practice.
Oncologists in our study did not appear to accept limits
placed on them by funding policy decisions. One possible
reason for this is that they did not accept these limits as
being legitimate or fair. Daniels has proposed that limits
would be accepted if guided by a process that highlights,
"a transparency about the grounds for decisions; appeals
to rationales that all can accept as relevant to meeting
health needs fairly ... and that connect well with the goals
of various stakeholders in the many institutional settings
where these decisions are made[9]." The participants in
this study did not feel engaged with the process used toBMC Health Services Research 2007, 7:193 http://www.biomedcentral.com/1472-6963/7/193
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make priority setting decisions and this may be a major
reason for not accepting limits. A previous survey of Cana-
dian oncologists reported that more than 80% of
respondents agreed that clinical practice guidelines were
good educational tools, convenient sources of advice, and
intended to improve quality of care; only 42% of the
oncologists surveyed felt that clinical practice guidelines
were intended to cut costs [10]. Our study suggests that
despite the positive attitudes towards practice guidelines,
which were integral to the NDFP's funding decisions[5],
efforts to improve oncologists' engagement in funding
policy decisions by the NDFP are required. One initial,
concrete step to improve engagement with clinicians
would be ensuring that they know as much as possible
about the decision-making processes used for cancer drug
funding decisions. Two previous papers[6,7] have
described the strengths of those processes but Singer's[7]
study reports that the reasoning behind those decisions
was not widely publicised outside the committee. Better
publicity about how decisions are made might not only
help engage oncologists but also help oncologists under-
stand that the decision makers are sometimes restricted by
the evidence based guidelines.
On the other hand, some oncologists may be unwilling to
accept any limits on care, no matter how fair the process.
Many of the participants in this study were willing to do
whatever was necessary to obtain funding for a drug they
felt would be beneficial for their patients. It may be that
one of the primary tenets of priority setting – that limits
must be set to meet population health needs in the face of
resource constraints – will not be easily accepted by phy-
sicians who see themselves solely as patient advocates
[11]. Policy makers will need to consider how they will
deal with physicians who will not accept limits to access-
ing drugs even if set by an "ideal" decision making body.
Three findings from this study may conflict and therefore
provide a useful starting point for further exploration.
First, at least some oncologists believe that at least some
priority setting decisions are limiting access to drugs that
are necessary for quality care. Second, many oncologists
appear to be spending a significant amount of time and
energy on administration and negotiation related to
accessing drugs in situations where access has been lim-
ited by policy makers. Third, most oncologists in this
study claimed that none of this affected the quality of
patient care. This begs several questions: When oncolo-
gists want access to drugs that policy makers have
restricted, are these oncologists right or wrong? Are 'med-
ically necessary' drugs being restricted and, if so, is that
wrong? Should oncologists be spending their time and
energy on getting access to restricted drugs or should this
time and energy be directed to patient care? If they spent
more time on patient care would this result in more
patients being seen and, perhaps, reduced waiting lists?
Certainly, further information from studies accurately
quantifying how much time is spent on activities to access
unfunded drugs would be useful in informing debates
generated by the last two questions.
According to our findings, priority setting decisions had a
significant impact on physician-patient relationships.
Communicating with patients effectively about difficult
subjects is important to maintain an effective and produc-
tive physician-patient relationship. Significant work has
been done to help improve communication about other
difficult topics like end-of-life care [12-14]. There are pro-
posed frameworks [15] on how to communicate effec-
tively about priority setting decisions and further work in
this area is warranted.
There are two major limitations to this study. First, since
this study described the views of a strategically selected
group of oncologists about their practices in response to a
specific priority-setting process at a given time, the find-
ings may not be generalizable to other physicians in dif-
ferent practice settings. As priority-setting processes evolve
(as they have in Ontario, where there is now a greater
influence of cost-effectiveness data), further research will
be needed to assess how physicians' practice is affected by
these processes. Second, the physicians in this study
shared their perceptions of how priority setting decisions
affected their practice – this may not coincide with their
actual practice. However, it is likely that lessons gleaned
from this study, and the questions it raises, can help pri-
ority setting decision makers, and clinicians who must
practice in the aftermath of their decisions.
Conclusion
In conclusion, this study has shown that when priority
setting decisions limit access to cancer medications,
oncologists' effort to overcome those limits have a signif-
icant impact on their practice. Policy makers need to seri-
ously consider the implications of their decisions on
physicians, who may go to considerable effort to circum-
vent their policies in the name of patient advocacy.
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Appendix 1
Interview Guide
Thank-you for agreeing to be interviewed for this study. The
purpose of this study is to describe the impact of Cancer Care
Ontario's New Drug Funding Program decisions on your prac-
tice. All responses will be kept completely confidential.
As you know, there are many new and expensive chemothera-
pies available for cancer patients. Cancer Care Ontario has a
funding program for new drugs that will pay for some of these
drugs for certain indications.
1. Tell me about how Cancer Care Ontario's New Drug
Funding Program has effected the quality of care you pro-
vide for your patients
2. Describe the effect Cancer Care Ontario's New Drug
Funding Program has had on your decisions to prescribe
new cancer chemotherapies.
3. Tell me about how have you dealt with situations where
you wanted to prescribe a drug for a patient, but the drug
was not funded. How has this changed since the New
Drug Funding Program started funding new drugs?
4. Describe the effect of either Cancer Care Ontario's New
Drug Funding Program on discussion of chemotherapy
treatment options with patients.
5. Tell me about the decisions of the New Drug Funding
Program that have had the biggest impact on your prac-
tice.
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